The glycopeptide analysis methods discussed here fall under the umbrella of glycopeptide characterization approaches developed for antibody-drug conjugates (ADCs). As the name suggests, ADCs consist of three parts: a cytotoxic drug, an antibody, and a linker between the two. The analysis of ADCs thus requires tracking both glycosylation that affects activity/PK as well as drug load and site heterogeneity.
ADCs are molecules of added complexity with multiple levels of structural heterogeneity. Differences exist not only within the antibody scaffold, cytotoxic agent, linker type, and drug-to-antibody ratio. Glycopeptide-level analytics are needed to verify glycosylation-dependent functionality is maintained and that conjugation of ADCs does not detrimentally impact crucial glycans.
Table 1 Structural Components and Analytical Considerations in ADC Characterization
| Structural Component | Heterogeneity Source | Glycopeptide Analysis Relevance |
| Antibody backbone | Glycoform microheterogeneity | Fc glycosylation integrity verification |
| Cytotoxic payload | Drug loading variability | Impact on glycan accessibility |
| Linker chemistry | Conjugation site selection | Site-specific occupancy assessment |
| Drug-to-antibody ratio | DAR distribution | Correlation with glycosylation patterns |
Antibody backbones are used as the carrier of ADCs. Antibodies can target antigens specifically and their Fc domains allow for glycosylation to mediate effector functions. Different cytotoxic agents such as microtubule inhibitors, DNA damaging agents, etc. all have different physiochemical properties that affect drug conjugation and stability of the ADC. The linker type affects drug release through different mechanisms. Cleavable linkers are designed to release the drug upon entering certain conditions within the cell. Non-cleavable linkers are dependent on lysosomal degradation to release the drug. Drug-to-antibody ratio (DAR) refers to the average number of drug molecules attached to each antibody molecule. A heterogeneous DAR can impact both the PK and efficacy of the ADC.
Antibody–drug conjugate structure.1,5
Fc glycosylation is also important for effector functions downstream of ADC cytotoxic killing such as antibody dependent cellular cytotoxicity (ADCC). The antibody N-glycan at Asn297 of the CH2 domain affects binding to Fc gamma receptors on immune cells which can provide a secondary mechanism to kill target cells. Glycosylation can impact ADC stability by helping to preserve the structural integrity of the Fc domain and forestall aggregation which can negatively affect manufacturing robustness and clinical efficacy. Glycosylation can also influence PK properties by interacting with clearance receptors modulating systemic exposure.
Structural characterization via intact mass does not offer much resolution for ADCs. Because intact mass cannot differentiate between glycoforms with similar mass shifts nor distinguish between payload conjugation sites vs. glycosylation modifications, released glycan analysis will not retain site information thus rendering it impossible to know whether conjugation impacts glycosylation sites differentially nor if glycosylation profiles of conjugated vs. unconjugated antibody species are the same. Site-specific glycopeptide analysis allows one to maintain linkage between the carbohydrates and the residue position, offering insights into how conjugation chemistry impacts glycosylation integrity. Site-specific glycopeptide analysis can also be used to correlate individual site-glycan combinations with functionality required for biosimilar characterization and quality monitoring.
Glycopeptide analysis of ADCs is the monitoring of glycosylation at the site-specific level that maintains linkage between glycans and the amino acid residues to which they are attached. This analysis technique provides insight to glycosylation related questions that arise uniquely with ADCs. For example, conjugation of a cytotoxic payload to an antibody can impact glycan processing or accessibility. Site-specific glycopeptide analysis can confirm that antibody effector function remains intact after conjugation, and that glycosylation is not negatively impacted.
After determining experimental conditions that will ensure complete digestion without harming the glycan or payload of interest, ADC glycopeptides are enzymatically digested to create peptides that include sites of glycosylation. These glycopeptides are then separated from unconjugated peptides, often on a reversed-phase column where payload addition changes the peptide retention time. Fragmentation of glycopeptides in high resolution/high mass accuracy tandem mass spectrometry creates ions that can be used to determine composition and site specificity. Glycan composition can be determined using collision-induced dissociation and peptide backbone fragmentation using electron-transfer dissociation.
Mapping of site-specific glycosylation is used to profile Fc region N-glycan on Asparagine 297 to confirm that conjugation chemistry has not impacted glycan structures necessary for binding to effector molecules. This measurement can identify shifts in glycosylation caused by conjugation chemistry such as altered terminal galactosylation or fucosylation that may occur due to chemical burden or glycan exposure to processing enzymes. Comparison of glycopeptide profiles between conjugated and unconjugated populations can reveal if certain glycoforms are preferentially conjugated or if the chemical modification is impacting the glycan structures necessary for binding to Fc receptors and immune cell recruitment.
The intent of glycosylation microheterogeneity analysis is to measure the relative amounts of the various glycoforms at a designated site. Each carbohydrate attached to a glycoprotein exists as a population of structurally similar molecules termed glycans. Microheterogeneity analysis can reveal subtle differences in glycans that could impact therapeutic potency or PK. Glycoforms present at very low levels may also be detected. These glycoforms, while representing only a small fraction of the overall glycans, may have high importance in function or could be exposed differently for conjugation. Relative quantification is used to determine the percentage of each glycoform present. Quantification may show the percentage of high mannose, complex, hybrid, sialic acid capped or free, and so on. Monitoring glycosylation site microheterogeneity can assist in process validation efforts by determining batch-to-batch consistency of glycosylation after conjugation. Glycosylation content should fall within an established acceptance range.
Glycosylation and conjugation compete in a structural sense because conjugating a drug to an antibody can change its conformation in a way that affects glycosylation sites' exposure to glycosylation enzymes and deglycosylation. Glycosylation can also affect conjugation by changing the drug-attachment sites available as well as affecting drug-loading capacity. Therefore, it is important to fully characterize glycosylation after conjugation to avoid compromising glycosylation patterns that lead to effector functions and to avoid heterogeneous drug-loading.
Site modification during conjugation steps can lead to structural stresses that indirectly influence glycosylation or carbohydrate exposure. Modification of residues near glycosylation sites can affect the local microenvironment and subsequently alter the presentation of the N-glycan relative to protein. The specific chemistry used, and which amino acids are modified, can cause structural changes near this conserved Asn, potentially impacting domain stability. Alternatively, site-specific conjugation distal to the glycan can maintain native glycosylation.
Steric hindrance by glycans may affect drug-to-antibody ratio distribution by limiting availability of conjugation sites. When conjugating drugs to antibodies the Fc region glycan can sterically hinder chemical reagents from interacting with nearby residues, causing variable drug loading. The difference in charge and hydrophilicity between glycoforms may impact conjugation efficiency as well, since terminal sugars may increase or decrease the reactivity of adjacent functional groups.
Variability in glycosylation and drug conjugation also results in heterogeneous populations with diverse functional consequences such as antibody recognition and clearance from the body. Affinity to Fc receptors can change due to the steric effects of the conjugated drug(s) or shifts in glycosylation angle, altering effector functions like ADCC. This highlights the importance of understanding how the pairing of a specific glycan at a certain site with a drug will affect cell recruitment. Clearance may also differ based on conjugation and glycoform as these can alter the rate of clearance and biodistribution.
Glycopeptide mapping is a critical analysis used throughout the ADC lifecycle including lead selection, commercial production and post approval portfolio management. Site-specific analysis allows monitoring of the effects conjugation chemistries have on Fc glycosylation. Confirmation that glycosylation pattern alterations do not impact effector functions and tightly control critical quality attributes during process improvement and regulatory variations.
Glycopeptide analysis done early in discovery helps antibody candidates be assessed for site-specific glycosylation that may be detrimental to conjugation efficiency or loss of desired effector functions. Differences between conjugation chemistries can also be compared to assess whether attachment of linker-payload impacts glycans at the Fc region or introduces unwanted microheterogeneity. Identifying glycosylation liabilities such as high mannose content or non-human glycan epitopes early on allows the selection of antibodies and conjugation chemistries that retain glycan profiles while still producing homogeneous drug-to-antibody ratios, limiting liabilities down stream and shortening time to clinical candidates.
Glycopeptide analysis during process development can help to determine the stability of Fc glycosylation after conjugation. Process chemistries should not introduce structural distortions or remodeling of glycans during production. Glycopeptide characterization ensures no structural changes have occurred due to manufacturing stresses (temperature, pH, exposure to reagents/conjuagents) upon process scale-up. Testing ensures consistent glycoform distribution at small and large scales. Process development will correlate sites of glycosylation with various process parameters in order to create design spaces that bracket important quality attributes. Glycopeptide testing can ensure conjugation chemistries are robust and translate well from discovery scale to commercial production without affecting the effector functions of the antibody or stability of the payload.
Batch-to-batch consistency is shown through glycopeptide analysis since glycoforms can drift between batches. Site-specific resolution provides higher resolution of the glycoform profile which may uncover discrepancies hidden by more global methods. In addition, analysis can demonstrate that conjugation does not impact glycosylation profiles or distribution of drug loading between batches manufactured at different times or with minor variations in starting materials. Stability studies of the product can be supported by glycopeptide analysis to determine if glycans are lost, payload is lost, or chemically modified during storage.
Glycopeptide analysis can also be required to fulfill lifecycle needs for comparability purposes after a post approval change to the process including site transfers, scale-up and master batch failures, conjugation chemistry optimizations etc. The site-specific glycan characterization provides evidence to regulatory agencies that glycosylation modifications to the Fc do not occur and that new glycans are not introduced with the process changes that could have implications on effector function or immunogenicity. This structural evidence can assist sponsors to successfully link the modified process to remain within design space or meet requirements for biosimilarity to the product before the change.
Techniques suited for ADC glycopeptide analysis are based on high resolution mass spectrometry (MS) coupled with tailored fragmentation approaches. Since ADCs are inherently heterogeneous molecules with respect to glycan microheterogeneity, DAR distribution and site specific conjugation the mass spectrometry platforms should provide qualitative evidence to resolve these features.
MS analyzers capable of providing high mass accuracy and resolution, such as Orbitrap and quadrupole-time-of-flight instruments are required to resolve ADC glycopeptides with varying numbers of drugs and glycans. The mass difference between conjugated and non-conjugated molecules is easily resolved which allows for accurate determination of site-specific drug-to-antibody ratios. Coupling complementary fragmentation techniques such as higher-energy collisional dissociation (HCD) and electron-transfer dissociation (ETD) provides both glycan structure through glycan oxonium ions and Y fragments from HCD and peptide-glycan linkage retention from ETD allowing for confident localization of glycosylation and drug attachment sites.
The separation between glycopeptides with drug conjugated and not conjugated takes advantage of retention time difference chromatographically and mass shifts spectrometrically due to the hydrophobic nature of the payload. Drug conjugation will typically prolong retention on a reversed-phase media allowing physical separation between various DAR species of the same glycopeptide. The attached drug adds a predictable mass shift that can be seen by mass spectrometry allowing for all unconjugated, monoglycosylated, and diglycosylated species to be monitored at the same time. Separating between glycopeptides that are drug loaded and not allows for the determination if glycoforms favor conjugation at certain sites and the degree to which all glycoforms of the antibody are drug loaded uniformly.
Relative quantitation is possible by integrating areas under extracted ion chromatograms. From these areas you can determine the relative amounts of high-mannose vs afucosylated vs galactosylated vs sialylated glycans, for example, present on one site after separation from other species and potential matrix signals. This can tell you if certain glycoforms are preferentially conjugated due to differences in accessibility or chemistry. Additionally, if your detection method is sensitive enough you can detect low abundance species which may contribute to effector function, monitor batch-to-batch variations and correlate site occupancy with potency or PK changes.
Advanced software platforms employ dedicated algorithms that consider the mass-shift and fragmentation effects of drug loads to match experimental data with libraries containing all possible drug adducts. Automated assignment engines streamline complex ADC data but leave spectra with incomplete assignments for subsequent manual curation. Manual inspection validates assignment of key spectra for glycan assignment verification, glycosite and conjugation site co-location and removal of artifact noise. Together these steps qualify the quantitative and structural fidelity producing submitted documents for chemistry, manufacturing and controls.
Guidance for regulatory submissions involving ADCs related to structure analysis include chemistry, manufacturing and controls information that highlights the unique nature of ADCs. Requirements include thorough analysis of ADC quality attributes such as glycosylation, drug-loading, and site occupancy to support consistency, safety and efficacy during development and commercial production.
CMC requirements for ADCs typically involve a significant amount of characterization to explain structural complexities due to non-uniformity of drug conjugation and glycosylation. Agencies want characterization around stability of the antibody backbone, linker, and payload to prove that the drug product made is the same every time. Attributes such as glycosylation, DAR, and free drug should be monitored together to understand how to best control the multitude of factors that go into ADCs during manufacturing and during their lifecycle.
Glycosylation is an important quality attribute in ADCs since glycan moieties attached to the Fc region can alter effector function, stability and pharmacokinetics. The composition of N-glycan at position Asn297 alters affinity for Fc gamma receptors and complement proteins, which affect antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), respectively. These activities work alongside the killing mediated by the cytotoxic payload. Guidelines require control over glycosylation since changes in fucosylation and galactosylation can alter potency, safety, and clearance.
Investigational new drug applications and Biologics license applications supported with structural characterization will need data to show that the glycosylation of ADCs as well as conjugation pattern match those of the reference material and are consistent between scales of manufacture. Site-specific glycopeptide analysis would be expected to be included in the structure characterization section of the chemistry, manufacturing, and controls. These studies should demonstrate lot-to-lot consistency and stability. For submissions to regulatory agencies worldwide, comparability studies are needed to evaluate how a change in manufacturing impacts glycosylation and drug loading, and that the post-change product will perform in the same manner as the pre-change product in terms of quality, safety, and efficacy.
Risk-based control plans help manage the heterogeneity of ADCs (different drug-to-antibody ratios, site selectivity of conjugation, glycoform microheterogeneity), specifying acceptance criteria and controlling processes based on sound scientific rationale. For example, focusing on variations that are known or predicted to affect PK, efficacy, and safety profile, risk-based controls allow the user to focus on controlling these attributes to an appropriate level rather than attempting to unrealistically control ADC heterogeneity to achieve homogeneity. Fully characterizing the molecule during development should allow for identification of a design space in which glycosylation/conjugation variations do not shift, giving the user the ability to control manufacturing variability. Additionally, using nonclinical and clinical data, acceptable ranges of batch-to-batch heterogeneity should be able to be defined.
The analysis of glycopeptides derived from ADCs presents several challenges. The difficulty lies in the structural complexity inherent to ADCs - they are comprised of both protein glycosylation as well as attached chemotherapeutics. Special considerations must be taken when analyzing these glycopeptides since carbohydrate modifications and drug loads can impact mass spectrometric outputs. The information obtained from these outputs must be interpreted in a way that accurately reflects structural variations and allows for precise quantitation.
Specific strategies to optimize ADC based on PK/PD.2,5
The existence of both heterogeneous glycoforms and variable DAR leads to complex mass spectra. Shifting of glycoform masses overlaps with peaks representing attachment of payloads. The spectra can become difficult to decipher because peaks of unique glycan-drug combinations may not correspond to unique mass shifts due to overlapping nominal masses. Resolution of glycoforms from unconjugated species and species with varying DAR necessitates high mass accuracy and deconvolution of isotopic patterns to precisely identify site-specificity.
Intercalated payloads have inherent fragmentation signatures during MS/MS analysis that can complicate glycan-specific ion recognition. Fragments from the payload moiety can be abundant and overwhelm the spectrum, hiding glycan-specific oxonium ions or peptide backbone fragments required for localization. Linker/drug chemistry can bias fragmentation patterns away from fragments that allow for full structural characterization. Targeted fragmentation and data filtration can help discern glycan-specific ions from payload fragmentation.
Quantitative analysis of ADC glycopeptides is complicated by variations in ionization efficiencies between glycoforms and suppression effects of conjugation on the analyte signal. Often used cytotoxic payloads are hydrophobic which leads to ionization efficiencies different from that of non-conjugated antibodies. This affects the relative abundance determination and could lead to inaccuracies when comparing different batches. Reliable quantitation requires appropriate normalization and use of isotopically labeled internal standards when possible. The assay must be shown to be linear and reproducible over the anticipated range of drug loads.
Analytical reproducibility between conjugation batches can be difficult because chemical conjugation reactions can be variable. Reaction efficiencies and specificities may differ slightly between conjugation batches due to differences in reaction conditions, reagent lots, or antibody glycosylation microheterogeneity. These differences can impact the resulting glycoform distribution and drug-to-antibody ratio of the conjugate. Robust analytical methods with defined acceptance criteria, good system suitability checks, and statistical process control can help ensure that differences between batches are real and not due to analytical variability.
Complete ADC glycopeptide analysis deliverables package large amounts of analytical information into organized reports that can be used to drive development and meet regulatory needs. They offer conclusive documentation on how conjugation chemistry impacts antibody glycosylation for use in quality control, batch comparisons, and CMC filing.
Table 2 Deliverables from ADC Glycopeptide Analysis
| Deliverable Type | Content Description | Strategic Application |
| Site-specific maps | Glycan distribution per site in ADC context | Conjugation impact assessment |
| Quantification data | Relative glycoform and DAR variant abundance | Batch consistency monitoring |
| Annotated spectra | Fragment ion assignments with payload signatures | Structural verification |
| Technical reports | Comprehensive CMC documentation | Regulatory submission support |
Site-specific glycosylation maps display the distribution of glycans at each Asn residue, and can differentiate between glycans present on conjugated and unconjugated antibodies. This visualization allows one to see how drug conjugation influences glycan accessibility at individual sites, often seen in the Fc region. When displayed along with drug load data, glycoform distributions provide a quick way to determine if conjugation chemistries are altering specific glycans or introducing structural changes that shift microheterogeneity critical for mediating activity.
Relative quantification reflects the distribution of glycans among the different DAs which directly shows the correlation between glycosylation heterogeneity and conjugation heterogeneity. For example, relative quantification will show how abundant a glycoform is among the unconjugated species, singly-conjugated species, and multiply-conjugated species. Relative quantification can show if certain sugar structures are more prone to chemical conjugation. Ultimately, the relative quantification numbers can be used when determining specifications for glycosylation-related CQAs and drug load quantification.
Detailed tandem mass spectra are used to unambiguously confirm ADC glycopeptide assignments and annotate fragment ions that allow for differentiation between glycan-specific fragmentation and drug-related product ions. Each spectrum contains diagnostic oxonium ions that validate glycan content as well as backbone b and y ions that confirm peptide sequences with drug-modifications labeled by their respective mass shifts. The localization of the site of conjugation can be confirmed by fully annotating the spectra. Showing detailed spectra allows readers to understand how information was gathered and that proper glycan verification and site localization has been completed.
Regulatory package-ready technical documents summarize the glycopeptide analysis results into polished documents ready for inclusion in chemistry manufacturing and controls portions of an IND submission or biologics license application. These documents include assay development efforts specific to ADC complexity including analytical methods that consider conjugation chemistry in sample preparation methods and limits of data interpretation (i.e., can differences in glycans be differentiated from drug load). Documents typically include tables summarizing site and glycoform ratios with drug loading levels, sample chromatograms showing resolved conjugates and batch trend data that can stand alone to show the ADC structure needed for quality and control reviews by regulatory agencies.
Antibody-drug conjugates (ADCs) represent one of the most structurally complex classes of biologics, combining monoclonal antibodies, cytotoxic payloads, and linker chemistries into a single heterogeneous molecule. Accurate glycopeptide characterization in ADCs requires not only advanced LC-MS capability, but also a deep understanding of bioconjugation chemistry, drug-to-antibody ratio (DAR) distribution, and regulatory expectations for complex biologics. Our team delivers scientifically rigorous, development-stage-aligned glycopeptide analysis that supports informed decision-making throughout ADC discovery, development, and commercialization.
ADC characterization goes beyond traditional monoclonal antibody analysis. Drug conjugation introduces additional layers of structural heterogeneity that can influence peptide fragmentation behavior, glycosylation stability, and data interpretation. Our expertise includes:
By leveraging high-resolution LC-MS/MS platforms and optimized digestion workflows, we generate reliable glycopeptide data even in the presence of conjugation-induced complexity.
In ADCs, glycosylation and conjugation are not independent variables. Drug attachment can influence Fc structure, potentially altering glycan accessibility, microheterogeneity, or receptor binding properties. A comprehensive analytical approach must consider both modifications simultaneously. Our integrated strategy enables:
This holistic understanding ensures that glycopeptide characterization contributes meaningfully to structural risk assessment and product quality evaluation.
Each ADC program presents unique analytical challenges depending on antibody format, conjugation chemistry, payload properties, and development stage. We design tailored glycopeptide characterization strategies that align with your specific scientific and regulatory objectives. For early-stage development, we support:
For process development and scale-up, we focus on:
Our flexible approach ensures analytical depth is proportionate to development risk and program milestones.
Regulatory agencies expect comprehensive structural characterization for ADCs, including clear documentation of molecular heterogeneity and critical quality attributes. We generate glycopeptide analysis reports designed for seamless integration into CMC modules and regulatory submissions. Our deliverables include:
Throughout each project, we maintain transparent timelines, defined milestones, and consistent technical communication. Clients receive proactive updates, early identification of analytical risks, and scientifically grounded guidance to support strategic development decisions. By combining advanced analytical technology with deep expertise in complex bioconjugates, we provide a reliable and regulatory-aligned partner for ADC glycopeptide characterization across the full product lifecycle.
References
